818 related articles for article (PubMed ID: 18299307)
1. A randomized, controlled trial comparing twice-a-day insulin glargine mixed with rapid-acting insulin analogs versus standard neutral protamine Hagedorn (NPH) therapy in newly diagnosed type 1 diabetes.
Hassan K; Rodriguez LM; Johnson SE; Tadlock S; Heptulla RA
Pediatrics; 2008 Mar; 121(3):e466-72. PubMed ID: 18299307
[TBL] [Abstract][Full Text] [Related]
2. Injection of acidic or neutral insulin and pain: a single-center, prospective, controlled, noninterventional study in pediatric patients with type 1 diabetes mellitus.
Karges B; Muche R; Riegger I; Moritz M; Heinze E; Debatin KM; Wabitsch M; Karges W
Clin Ther; 2006 Dec; 28(12):2094-101. PubMed ID: 17296465
[TBL] [Abstract][Full Text] [Related]
3. Twice-a-day insulin glargine mixed with rapid-acting insulin analogs versus standard neutral protamine Hagedorn therapy for newly diagnosed type 1 diabetes.
Al Shamsi AM
Pediatrics; 2008 Sep; 122(3):675-6; author reply 676. PubMed ID: 18762540
[No Abstract] [Full Text] [Related]
4. Basal insulin switch from NPH to glargine in children and adolescents with type 1 diabetes.
Päivärinta M; Tapanainen P; Veijola R
Pediatr Diabetes; 2008 Jun; 9(3 Pt 2):83-90. PubMed ID: 18221431
[TBL] [Abstract][Full Text] [Related]
5. Comparison of incidence of acute myocardial infarction in patients with type 2 diabetes mellitus following initiation of neutral protamine Hagedorn insulin versus insulin glargine.
Rhoads GG; Kosiborod M; Nesto RW; Fonseca VA; Lu SE; Zhang Q; Foody JM
Am J Cardiol; 2009 Oct; 104(7):910-6. PubMed ID: 19766755
[TBL] [Abstract][Full Text] [Related]
6. Initiation of insulin glargine in children and adolescents with type 1 diabetes.
Tan CY; Wilson DM; Buckingham B
Pediatr Diabetes; 2004 Jun; 5(2):80-6. PubMed ID: 15189493
[TBL] [Abstract][Full Text] [Related]
7. Dosing of insulin glargine in the treatment of type 2 diabetes.
Barnett A
Clin Ther; 2007 Jun; 29(6):987-99. PubMed ID: 17692716
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of conversion from bedtime NPH insulin to morning insulin glargine in type 2 diabetic patients on basal-prandial insulin therapy.
Yokoyama H; Tada J; Kamikawa F; Kanno S; Yokota Y; Kuramitsu M
Diabetes Res Clin Pract; 2006 Jul; 73(1):35-40. PubMed ID: 16513202
[TBL] [Abstract][Full Text] [Related]
9. Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir.
Peterson GE
Curr Med Res Opin; 2006 Dec; 22(12):2613-9. PubMed ID: 17166343
[TBL] [Abstract][Full Text] [Related]
10. Insulin glargine: a new once-daily basal insulin for the management of type 1 and type 2 diabetes mellitus.
Lam S
Heart Dis; 2003; 5(3):231-40. PubMed ID: 12783637
[TBL] [Abstract][Full Text] [Related]
11. Twice-daily compared with once-daily insulin glargine in people with Type 1 diabetes using meal-time insulin aspart.
Ashwell SG; Gebbie J; Home PD
Diabet Med; 2006 Aug; 23(8):879-86. PubMed ID: 16911626
[TBL] [Abstract][Full Text] [Related]
12. Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: insulin pump therapy versus multiple daily injections.
Bode BW
Clin Ther; 2007; 29 Suppl D():S135-44. PubMed ID: 18191065
[TBL] [Abstract][Full Text] [Related]
13. Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products.
Bullano MF; Al-Zakwani IS; Fisher MD; Menditto L; Willey VJ
Curr Med Res Opin; 2005 Feb; 21(2):291-8. PubMed ID: 15802000
[TBL] [Abstract][Full Text] [Related]
14. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
Hauner H; Kohlmann T; Landgraf W; Holle R; Pirk O; Scholten T
Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
[TBL] [Abstract][Full Text] [Related]
15. [New methods in insulin treatment].
Neuwirth G
Orv Hetil; 2005 Jan; 146(3):111-6. PubMed ID: 15693442
[TBL] [Abstract][Full Text] [Related]
16. The impact of insulin glargine on clinical and humanistic outcomes in patients uncontrolled on other insulin and oral agents: an office-based naturalistic study.
Fischer JS; McLaughlin T; Loza L; Beauchamp R; Schwartz S; Kipnes M
Curr Med Res Opin; 2004 Nov; 20(11):1703-10. PubMed ID: 15537471
[TBL] [Abstract][Full Text] [Related]
17. Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors.
Ceriello A; Del Prato S; Bue-Valleskey J; Beattie S; Gates J; de la Peña A; Malone J
J Diabetes Complications; 2007; 21(1):20-7. PubMed ID: 17189870
[TBL] [Abstract][Full Text] [Related]
18. Parental preference of prandial insulin aspart compared with preprandial human insulin in a basal-bolus scheme with NPH insulin in a 12-wk crossover study of preschool children with type 1 diabetes.
Danne T; Råstam J; Odendahl R; Näke A; Schimmel U; Szczepanski R; Moeller J; Deiss D
Pediatr Diabetes; 2007 Oct; 8(5):278-85. PubMed ID: 17850471
[TBL] [Abstract][Full Text] [Related]
19. Benefits of continuous subcutaneous insulin infusion in type 1 diabetes previously treated with multiple daily injections with once-daily glargine and pre-meal analogues.
Torres I; Ortego J; Valencia I; García-Palacios MV; Aguilar-Diosdado M
Exp Clin Endocrinol Diabetes; 2009 Sep; 117(8):378-85. PubMed ID: 19629931
[TBL] [Abstract][Full Text] [Related]
20. A randomized trial comparing the rate of hypoglycemia--assessed using continuous glucose monitoring--in 125 preschool children with type 1 diabetes treated with insulin glargine or NPH insulin (the PRESCHOOL study).
Danne T; Philotheou A; Goldman D; Guo X; Ping L; Cali A; Johnston P
Pediatr Diabetes; 2013 Dec; 14(8):593-601. PubMed ID: 23730996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
